HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies

Eli Lilly and Novo Nordisk are building cases for their incretin drugs, both new and old, as attractive weight loss maintenance options and a potentially speedier option to shed pounds, respectively.

By FiercePharma · May 14, 2026 · via FiercePharma
Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
STAT+: Gene therapy viruses linked to a boy’s tumor
PipelineSTAT News ↗
STAT+: Gene therapy viruses linked to a boy’s tumor
The case for Makary as the WOAT, Cassidy's seat at risk ahead of midterms, and other biotech news from The Rea…
May 13, 2026
Alkermes’ Lumryz clears phase 3 in idiopathic hypersomnia, intensifying Jazz rivalry
PipelineBriefing
Alkermes’ Lumryz clears phase 3 in idiopathic hypersomnia, intensifying Jazz rivalry
Three months post-Avadel acquisition, Alkermes’ Lumryz met all endpoints in the phase 3 Revitalyz study for id…
May 13, 2026
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
PipelineSTAT News ↗
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the pro…
May 13, 2026